Chen F, et al. - Dexmedetomidine (DEX) was tested for the efficacy as a preventative and treatment for emergence agitation (EA) in children when administered as a rapid bolus in different doses. Participants were 100 patients who were randomly divided into five groups: the control group (group D1), the 0.25 μg/kg DEX group (group D2), the 0.5 μg/kg DEX group (group D3), the 0.75 μg/kg DEX group (group D4), and the 1 μg/kg DEX group (group D5). Findings demonstrated that an improved recovery profile could be obtained as a result of reduced EA incidence consequent to rapid intravenous injection (IV) bolus administration of 0.75 and 1.0 μg/kg of DEX in children. Clinically, good tolerability of DEX was seen in children, although its use resulted in a transient decreases in heart rate and mean blood pressure.